Utama › Myasthenia Gravis › California

Kajian klinikal Myasthenia Gravis di California

20 kajian untuk Myasthenia Gravis sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Neurology Center of North Orange County, Fullerton
The Neurology Group, Pomona

Mengambil pesertaFasa 3

Umur 18 hingga 74 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07217587

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

Cinical Study Site, Pasadena

Mengambil pesertaFasa 3

Umur 18 hingga 80 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07647510

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Profound Research LLC - Carlsbad, Carlsbad

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07294170

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Profound Research LLC - Carlsbad, Carlsbad

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07284420

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Tri Valley Neurology Medical Associates Inc., Mission Hills

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07501702

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

TG Therapeutics Investigational Trial Site, La Jolla

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06680037

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

University of California Irvine Medical Center, Irvine

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT06414954

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Hoag Memorial Hospital Presbyterian, Newport Beach
Stanford Neuroscience Health Center, Palo Alto

Mengambil pesertaFasa 1

Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT07304154

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

University of California Irvine, Orange
UC Davis, Department of Neurology, Sacramento
University of California, San Francisco, San Francisco

Mengambil pesertaFasa 1/2

Umur 18 hingga 70 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT06359041

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

University of California-San Francisco, San Francisco

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan

Umur 18 hingga 64 · Wanita · Dikemas kini 11 Ogo 2026 · NCT06940323

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Aurinia Investigational Site, Pasadena

Mengambil pesertaFasa 1/2

Umur 18 hingga 85 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT07596901

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Lucile Packard Children's Hospital Stanford, Palo Alto
UCSF Benioff Children's Hospital, San Francisco

Mengambil pesertaFasa 2/3

Umur 2 hingga 17 · Semua jantina · Dikemas kini 31 Jul 2026 · NCT05265273

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Site Number - 1010, Carlsbad
Site Number - 1028, Irvine
Site Number - 1023, Los Angeles
dan 2 lagi

Mengambil pesertaFasa 3

Umur 18 hingga 80 · Semua jantina · Dikemas kini 30 Jul 2026 · NCT07039916

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Ronald Reagan UCLA Medical Center, Los Angeles
University of California, Irvine, Orange
Stanford University Medical Center, Palo Alto

Mengambil pesertaFasa 2/3

Umur 18 hingga 75 · Semua jantina · Dikemas kini 29 Jul 2026 · NCT06193889

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Care Access Research, Pasadena

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT04951622

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

University of Southern California, Los Angeles
University of California Irvine, Orange
University of California San Francisco (UCSF), San Francisco

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 18 Jun 2026 · NCT06456580

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

UCLA Medical Center, Los Angeles
University of California, Irvine, Orange
Stanford Hospital, Palo Alto

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT06626919

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Clinical Trial Site, Fresno
Clinical Trial Site, Orange
Clinical Trial Site, Rancho Mirage
dan 1 lagi

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT04202341

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,, San Francisco

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 17 Feb 2026 · NCT06298565

Vitaccess Real MG Registry

UCI Health, Orange

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2025 · NCT06064461

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.